← Leaderboards
Jing Yang
Aplexis, Inc.
$2,599,872
Attributed
$2,599,872
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$2,599,872 · 2
By mechanism
R44$2,202,674 · 1
R43$397,198 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Rising Stars on “Fda Approved”
- Suma Babu · Massachusetts General Hospital$26,348,733
- Sabrina Paganoni · Massachusetts General Hospital$26,348,733
- Michael Difilippantonio · Leidos Biomedical Research, Inc.$22,364,766
- Michael George Natchus · Emory University$10,548,554
- John Alam · Eip Pharma, Inc.$10,411,018
- George Gaitanaris · Omeros Corporation$6,689,019
Research focus
Fda ApprovedGenerationsArteriesEffective TherapyFoundationsFutureBinding ProteinsBiometryBlood Cell CountAspirinEnsureAnemiaCellsBindingChronicChronic PhaseClinical CandidateClinical ManagementClinical TrialsCollaborationsComplicationDrug KineticsBone MarrowGenetic Study
Grant awards (3)
Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis$1,101,337
R44 · FY2025 · HL · contact PI
Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis$1,101,337
R44 · FY2024 · HL · contact PI
Developing small molecule inhibitors of Pleckstrin-2 to treat thrombosis$397,198
R43 · FY2022 · HL · contact PI